Loading…

Investment firm Gyrus Capital signed an agreement to acquire LivaNova's heart valve business for an enterprise value of €60 million, including plants in Italy and Canada.
“The LivaNova HV business is a global player in surgical heart valves with world-class products and compelling growth opportunities.”medicaldevice-network.com
Summarized from public sources; check the original articles before acting on it.